FDA “determined a more streamlined pathway” using information it's received for products available under enforcement discretion “would help provide for the long-term availability and marketing of many” of those products.
Results from the US Food and Drug Administration’s and manufacturers’ responses this year to an infant formula shortage pointed the agency to plan to streamline its procedures for allowing additional firms to market formula.
The agency on 6 July announced it has “determined that a more streamlined pathway” using information it has received for...
Create an account to read this article
Already a subscriber?
Health and wellness brands and retail chains providing access to prescriptions for compounded GLP-1 drugs, most also offering supplements curated to help meet dietary needs of GLP-1 patients, are offering formulations in oral form as well as injection.
HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.
As firms in OTC drug, dietary supplement and personal care/beauty sectors reported results for January-March period after Trump announced reciprocal tariffs, they buckled up for more changes in the president’s thinking likely to affect consumer spending as well as their costs.
Potential for supply disruption coupled with manufacturers’ costs for moving supply chains to US emphasized by industry trade groups in comments submitted to Department of Commerce on whether pharmaceutical and dietary ingredients should remain exempted from tariffs President Trump has imposed.
Nature’s Bounty, Osteo Bi-Flex and Puritan’s Pride are among the dietary supplement brands under strategic review by Nestle as the firm shifts its focus to the premium end of the market.
New York-based Interparfums has signed a deal with Parisian firm Longchamp – known for its leather goods – for the creation and distribution of fragrance lines.
What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.
